HIPEC Clinical Trial Now Open
Secondary Cytoreductive Surgery + HIPEC for Recurrent Mucinous Ovarian Cancer
(HI-MOC Study)
An-going study underway at MD Anderson Cancer Center is recruiting and enrolling women who qualify. It is led by Dr. Aaron
Shafer, a member of the MOCC Physician Advisory Committee.
This clinical trial is focused on women with recurrent primary Mucinous ovarian cancer. The goal? To better understand overall survival after secondary cytoreductive surgery combined with HIPEC. Researchers are currently enrolling women who meet eligibility requirements.
If you or someone in your care may qualify, now is the time to explore this option.
What Is HIPEC?
HIPEC stands for hyperthermic intraperitoneal chemotherapy. It’s a two-step treatment performed during surgery:
Step 1: Tumor Removal
The surgeon removes all visible tumors and diseased tissue from the abdominal cavity (this is called cytoreductive surgery).
Step 2: Heated Chemotherapy
After tumor removal, heated chemotherapy is delivered directly into the abdomen through a catheter. A specialized perfusion machine circulates the warmed chemotherapy throughout the abdominal cavity for about one to two hours.
Once complete, the chemotherapy is drained, the abdomen is rinsed with a sterile solution, and the incision is closed.
The idea behind HIPEC is simple: deliver concentrated, heated chemotherapy exactly where it’s needed — right at the source.
Interested? Here’s How to Learn More
If you believe you or a patient in your care may be a candidate for this trial at MD Anderson Cancer Center:
Call: 832-885-6133
Email: AShafer@mdanderson.org
You can also view full study details on the National Library of Medicine’s ClinicalTrials.gov website.
Help Fund Research for Mucinous Ovarian Cancer
Mucinous ovarian cancer remains significantly underfunded. Rhonda’s Award is one of the only dedicated funding programs in the world focused specifically on this rare subtype.
When you donate to MOCC, you help expand critical research efforts — from early detection to better treatment options. Every gift makes a difference. Join us in funding the future of Mucinous ovarian cancer research by making an online contribution today!
